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Abstract
Background: Pomegranate fruit has been shown to exhibit the inhibitory activity against prostate cancer and lung
cancer in vitro and in vivo, which might be a resource for chemoprevention and chemotherapy of cancer. Our
previous documented findings indicated that treatment of urinary bladder urothelial carcinoma cell with the
ethanol extract isolated from the juice of pomegranate fruit grown in Taiwan could inhibit tumor cell. In this study
we intended to uncover the molecular pathway underlying anti-cancer efficacy of Taiwan pomegranate fruit juice
against urinary bladder urothelial carcinoma.
Methods: We exploited two-dimensional gel electrophoresis coupled with tandem mass spectrometry to find the
de-regulated proteins. Western immunoblotting was used to confirm the results collected from proteomics study.
Results: Comparative proteomics indicated that 20 proteins were differentially expressed in ethanol extract-treated
T24 cells with 19 up-regulated and 1 down-regulated proteins. These de-regulated proteins were involved in
apoptosis, cytoskeleton regulation, cell proliferation, proteasome activity and aerobic glycolysis. Further studies on
signaling pathway demonstrated that ethanol extract treatment might inhibit urinary bladder urothelial carcinoma
cell proliferation through restriction of PTEN/AKT/mTORC1 pathway via profilin 1 up-regulation. It also might evoke
cell apoptosis through Diablo over-expression.
Conclusions: The results of this study provide a global picture to further investigate the anticancer molecular
mechanism of pomegranate fruit.
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Background
Bladder cancer is the most prevalent tumor of the urin-
ary tract worldwide and ranked the 15th in cancer mor-
tality rate in 2011 in Taiwan [1, 2]. Urothelial carcinoma
is the most common and constitutes more than 90 % of
bladder cancer cases in developed countries [3]. Accord-
ing to WHO/ISUP classification (2004), urinary bladder
urothelial carcinoma (UBUC) cell can be classified into
low and high grade while high grade UBUC cell is less
differentiated. Although most of UBUCs are papillary/
non-invasive or superficially invasive types and can often
be cured by curettage, some UBUCs can still develop
relentless local recurrence followed by lethal distal
spreading [4].
Pomegranate (Punicagranatum, Punicaceae), is an ed-
ible fruit cultivated in Mediterranean countries, India
and the United States etc., comprising edible portions of
80 % juice and 20 % seeds. Pomegranate contains crude
fibers, pectin, sugars, tannins (mainly ellagitannins),* Correspondence: wutingfe@stust.edu.tw
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flavonoids and anthocyanins. Among those nutritious in-
gredients, anthocyanins is believed to have provided the
fruit with potent antioxidant ability [5].
Many literatures have showed that pomegranate fruit
displays anti-cancer effectiveness. Ellagitannin-rich pom-
egranate fruit extract (PFE) purified from pomegranate
edible portion with 70 % acetone was found to have the
apoptotic effects on human lung cancer A549 cells
through the down-regulation of cell cycle-regulatory
proteins operative in the G1 stage and inhibiting NF-κB
as well as MAP kinase pathways [p38, phosphoinositide
3 kinase (PI3K)/ protein kinase B (Akt), c-jun N-terminal
kinase (JNK) and extracellular signal-regulated kinase
(Erk)] [6]. In the animal model of primary lung tumor,
PFE also diminishes tumor growth/progression/angiogen-
esis by the suppression of NF-κB, MAP kinase pathways
and mammalian target of rapamycin (mTOR) signaling
[7]. In addition to the impacts on lung cancer, PFE may be
a potential source for chemoprevention of prostate cancer
[8]. The investigations on prostate cancer found that
pomegranate polyphenols, ellagitannin-rich extract (PE)
prepared from fruit skins can retard prostate cancer likely
caused by chronic inflammation via suppressing the NF-
κB pathway [9]. PE was also observed to down-regulate
the angiogenesis in prostate cancer through down-
regulation of hypoxia-inducible factor 1-α (HIF-1α) which
transcriptionally regulates the vascular endothelial growth
factor (VEGF) expression [10]. Clinical trial with rising
prostate-specific antigen (PSA) after surgery or radiother-
apy indicated that after daily treatment with 8 oz of pom-
egranate juice a significant increase in mean PSA doubling
time from 15 months at baseline to 54 months post-
treatment [11]. Our previous documented results showed
that pomegranate juice could evoke prostate cancer cell
apoptosis via mitochondrial pathway and death receptor
signaling. It also can interfere with the expression levels of
genes involved in cytoskeletal functions, anti-apoptosis,
metabolism, NF-B signaling in juice-treated prostate
cancer cell [12].
Based upon the aforementioned documented findings,
pomegranate may be a potential chemopreventive re-
source against UBUC development and recurrence.
Our previous documented findings indicated that
treatment of the ethanol extract (PEE) of pomegranate
fruit juice could inhibit UBUC cell via cell cycle arrest
and cell apoptosis [13]. Thus in this study we exploited
two-dimensional gel electrophoresis (2-DE) coupled with
tandem mass spectrometry to decipher the molecular
mechanism underlying the cancer intervention of PEE.
We found that PEE treatment could inhibit UBUC cell
proliferation and migration. PEE-induced de-regulated
proteins were associated with apoptosis, cytoskeleton
regulation, AKT/mTOR signaling, proteasome activity
and aerobic glycolysis. These de-regulated proteins
might contribute to PEE-evoked inhibition of UBUC cell
proliferation and cell apoptosis.
Methods
Collection and identification of plant materials
The fruits of P. granatum were field collected from a farm
land (22°41′59.3267″ N, 120°30′45.1836″ E) located in a
small township Jiuru, Pingtung county, southern Taiwan
from August to September, 2012. The plant specimens
were identified by Dr. Gwo-Ing Liao from National
Chen-Kung University, Taiwan and were pressed/dried
for voucher specimens (Nan-Kai Lin, STUSTG308-001 to
STUSTG308-003) deposited in the herbarium of Taiwan
forestry research Institute (TAIF), Taiwan.
Preparation of ethanol extract (PEE) of pomegranate
fruit juice
PEE was prepared as described previously [13]. In brief,
fresh pomegranate fruit was peeled and juice was con-
centrated by freeze drying. The powder was first ex-
tracted with ethylacetate (EtOAc) at a ratio of 1:3 (w/v).
After extraction, the residue was collected by centrifuga-
tion and then extracted with 70 % (v/v) ethanol as de-
scribed in EtOAc extraction. The supernatant of ethanol
extraction was vaccum dried and the product was recog-
nized as PEE which was stored at −20 °C till future use.
Appropriate amount of PEE dissolved in DMSO was
used for anti-cancer assay and proteomics study.
Cell lines
Human UBUC T24 and J82 cells were used in this
investigation. Human UBUC T24 cell, which is recog-
nized as high grade and invasive, was purchased from
Bioresource Collection and Research Center, Hsinchu,
Taiwan and cultured at 37 °C in McCoy’s5A [GIBCO
(Life technologies), Grand Island, N.Y., U.S.A.], sup-
plemented with 10 % (v/v) fetal bovine serum (FBS).
UBUC J82 cells recognized as high grade was offered
by Dr. Chien-Feng Li from Department of Pathology,
Chi-Mei Medical Center, Tainan, Taiwan and main-
tained at 37 °C in Dulbecco’s Modified Eagle Medium
supplemented with 10 % (v/v) FBS (GIBCO, Grand
Island, N.Y., U.S.A.). TSGH8301 cell (low grade) was
derived from patients with superficial bladder cancer
in Taiwan [14] and provided by Dr. Chien-Feng Li in
2010 from Department of Pathology, Chi-Mei Medical
Center. TSGH8301 cell was cultivated at 37 °C in
RPMI-1640 (GIBCO)/10 % (v/v) FBS.
Isoelectric focusing (IEF) and SDS-polyacrylamide gel
electrophoresis (SDS-PAGE)
Preparation of protein lysates for two-dimensional gel
electrophoresis was described in an additional file
[Additional file 1]. IEF and SDS-PAGE was undertaken as
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described before with some modifications [12]. The
pH 4–7, 18-cm immobibline dry strips (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) were rehydrated using
BioRad Protean IEF Cell for 16 h at 20 °C with
300 μl rehydration buffer containing 100 μg protein
lysates prepared from PEE-exposed or 0.5 % (v/v)
DMSO (vehicle)-exposed T24 cells. The proteins were
then focused at 20 °C at 50 V, 100 V, 200 V, 500 V,
1000 V, 5000 V and 8000 V respectively with a total
of 81,434 voltage-hours.
Image analysis and statistical analysis
2-DE gels were stained with LavaPurple™ according to
manufacture’s protocol described in brief in an add-
itional file [Additional file 1]. Then the images of 2-DE
gel map were scanned using Typhoon 9400 fluorescence
scanner (GE healthcare) with green laser (green laser
PMT: 600 volt and emission filter: 580 BP). To search
for the de-regulated proteins in PEE-exposed T24 cells
for 36 h, a total of 9 pairs of well-focused gel maps
collected from control and PEE-treated T24 cells were
compared by PDQuest 8.0.1 (BioRad) software. Dys-
regulated expressed protein spots identified by computer
analysis were further confirmed by visualization. The
intensity of the spot was measured and normalized as
a percentage of the total intensities of all spots in a
gel (total normalized volume). For each differentially
expressed protein spot normalized volumes of individual
protein spots across replica gels of 0.5 % (v/v) DMSO- or
PEE-incubated T24 cells were first analyzed by the normal
distribution test and then Student’s t-Test (STATISTICA,
StatSoft, Tulsa, OK, U.S.A.) was carried out when normal
distribution was obtained. However, when normal distri-
bution was not acquired, log transformation was per-
formed followed by the normal distribution test and
Student’s t-Test. In all cases, statistical variance of the
PEE-exposed : control spot intensity ratio within 95 %
(Student’s t-Test; P < 0.05) was considered to be signifi-
cantly different. Furthermore the differentially expressed
proteins present at least in 5 out of 9 gel pairs were
regarded as PEE-impacted proteins.
In-gel digestion and protein identification analysis via
liquid chromatography-tandem mass spectrometry
(LC-MS/MS)
The protein spots of interest were picked up for in-gel
digestion using silver staining. The silver staining, in-gel
digestion and mass spectrometric protein identification
were performed as described previously [12]. Briefly, the
protein digest was separated in LTQ-Orbitrap hybrid
tandem mass spectrometer (ThermoFisher, USA) in-line
coupled with Agilent 1200 nanoflow HPLC system
equipped with LC Packing C18 PepMap 100 (length:
5 mm; internal diameter: 300 μm; bead size: 5 μm) as
the trap column and Agilent ZORBAX XDB-C18
(length: 50 mm; internal diameter: 75 μm; bead size:
3.5 μm) as the separating column. File Converter in Xca-
libur 2.0SR package (ThermoFisher, USA) and an in-
house program were used to extract the MS/MS infor-
mation as well as to compute the charge and mass for
each analyzed peptide. TurboSequest program (ver. 27,
rev. 11) was then used to search the best matched
peptides from a non-redundant protein database whose
FASTA sequences were downloaded from National
Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/guide/proteins/#tab-all_) on 2010/10/12 with
541927 entries. While only the tryptic peptides with ≦ 2
missed cuts were considered, the mass ranges during the
database search were 1 and 3.5m/z for fragment and pre-
cursor ions respectively. The protein identities were verified
only when there were at least two peptides matched and
both search results had high Xcore (i.e., ≧ 2.0 for doubly
charged peptides and ≧3.0 for triply charged ones) and
with minimal differences between observed and hypo-
thetical masses (i.e., ΔM <10 ppm). For each set of
MS/MS analyses, 25 fmol of BSA in gel was analyzed
in parallel for verification of effectiveness of the en-
tire protein identification procedure, including in-gel
digestion, nanoflow HPLC, MS/MS and informatics ana-
lyses. The experimental data were only taken into account
only when 10 ppm mass accuracy and over 70 % coverage
was observed for the co-processed BSA sample.
Western immunoblotting
After treatment as described in section 3, T24 or J82
cells were harvested and lysed in lysis buffer [10 mMTris
(pH 8.0), 0.32 M sucrose, 1 % (v/v) Triton X-100, 5 mM
EDTA, 2 mM DTT, and 1 mM PMSF]. After determin-
ing its protein concentration using Bio-Rad DC protein
assay kit, equal volume of 2× sample buffer [0.1 M Tris
(pH 6.8), 2 % (w/v) SDS, 0.2 % (v/v) β-mercaptoethanol,
10 % (v/v) glycerol, and 0.0016 % (w/v) bromophenol
blue] was combined with the protein lysate. Appropriate
amounts of the lysates were separated by electrophoresis
at 100 V with 10 % (w/v) SDS-PAGE, and further
transferred onto a PVDF membrane (Strategene, La
Jolla, CA, USA). After blocking for 1 h in 3 % (w/v)
bovine albumin serum (BSA) at room temperature, mem-
branes were hybridized overnight at room temperature
with primary antibodies listed in an additional file
[Additional file 1]. The membranes were washed and
probed with suitable secondary antibodies for 1 h at
room temperature. Secondary antibodies binding on
the membrane were detected by chemiluminescence
ECL detection system (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) using Fujifilm LAS-3000 Luminescent
Image Analyzer (Fujifilm Corporation, Tokyo, Japan). The
intensity of each protein band, normalized with actin or
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
protein expression level, was quantified by PDQUEST
Quantity One software (Bio-Rad Laboratory, Hercules,
CA) and analyzed with Student’s t-Test (STATISTICA,
StatSoft, Tulsa, OK, U.S.A.).
Results
Inhibitory impacts of PEE on outgrowth and migration of
UBUC cell
Our previous documented data demonstrated that PEE
might initiate a cascade of biochemical events to induce
UBUC cell apoptosis. In this study, we found that PEE
treatment temporally retarded T24 cell proliferation and
also could slow down T24 cell migration. The compar-
able impacts were also observed in PEE-incubated J82
cells (Fig. 1). PEE incubation also exerted the inhibitory
effects on low grade UBUC TSGH8301cell proliferation
(Fig. 1).
Two-dimensional gel electrophoresis of PEE-treated
T24 cells
To uncover the molecular mechanism underlying the
effects evoked by PEE, Lavapurple stained 2-DE gels
coupled with LC-MS/MS were conducted to profile
protein expression and search for those proteins whose
expressions were altered by PEE exposure. Since PEE
treatment showed a better impact on T24 cell prolifera-
tion /migration, T24 cell was chosen for subsequent pro-
teomics study. T24 cells treated for 36 h with or without
50 μg/mL PEE were selected for 2-DE analyses because,
as indicated by the results shown by Fig. 1f, sufficiently
affected cells that were at the same time still viable could
be collected and potentially relevant cellular changes
prior to cell death could typically be observed in
PEE-exposed T24 cells.
Initially 100 μg of proteins from mock and PEE-
incubated T24 cells were loaded and separated by 2-DE
of 18-cm gel strips (pI 4–7). To prevent the gel-to-gel
variation, nine replicate gel pairs were collected from
three independent treatments. The representative 2-DE
maps of un-treated and PEE-treated T24 cells were
depicted in Fig. 2 and the remaining 8 gel pairs were
shown in an additional file [Additional file 1].
The proteome maps of control and PEE-exposed T24
cells were compared to recognize the protein spot
variations. After PEE treatment, differentially expressed
protein features were recorded as described in Methods.
































































































































Fig. 1 Inhibitory influences of PEE on UBUC cells. a T24 cell proliferation assay. T24 cells were incubated with 50 μg/mL PEE for the indicated
times and cell proliferation was measured by cell counting assay as described in an additional file [Additional file 1]. The diagram was the typical
result of three independent experiments. All the data were expressed as mean ± standard deviation (S.D.) of the mean of four wells. b T24 cell
migration. T24 cells were incubated with 50 μg/mL of PEE for the indicated times and cell migration was observed as described in an additional
file [Additional file 1]. The results were expressed as mean ± S.D. of the mean of three independent experiments. c J82 cell proliferation assay.
d J82 cell migration. e TSGH8301 cell survival assay. f T24 cell survival assay for proteomics study. T24 cells were treated with 50 μg/mL PEE for the
indicated durations and cell viability was measured by MTT assay as described in an additional file [Additional file 1]. 0.5 % (v/v) DMSO-treated cells
were recognized as the control in all the assays. TSGH8301 cell was incubated with the indicated doses of PEE for 72 h and cell viability was measured
by MTT assay. 0 μg/ml indicated DMSO control. * and ** represented P < 0.05 and P < 0.001 respectively as compared to untreated cell using
Student’s t-test
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spots were found as denoted by the arrowed spots in
Fig. 2. Spots 3, 18 and A were close to 2-fold but statis-
tical significant (P < 0.05). The total normalized volume
(ppm) and statistical result of each protein spot were
presented in [Additional file 2: Table S1].
Identification of the differentially expressed proteins in
PEE-influenced T24 cells
After the proteome comparison, de-regulated proteins
were identified using LC-MS/MS as described in
Methods. The results of spectrometric analyses were
summarized in Table 1 and the matched peptides of
each de-regulated protein were shown in [Additional
file 2: Table S2]. The experimental molecular weight
and pI of each protein spot were near the theoretical
values, and most of the spectrometric protein cover-
ages were above 20 %.
The over-expressed proteins (spots 1–19) and under-
expressed proteins (spot A) were identified as described
in Table 1. Results of Ingenuity pathway analysis (IPA)
(Qiagen) showed that the identified de-regulated proteins
were involved in cell apoptosis (BCL10, CFL1, Diablo,
DUT, eIF5A, NDUFAF1, UBQLN1, TAGLN2), cell
proliferation (CAPZA1, PFDN5, PSMF1, PFN1, TPD52L2,
TSNAX), DNA metabolism (DUT, PFN1, POL3, UBQLN1),
proteasome (UBQLN1), glycolysis (TPI1), cytoskeleton
(CAPZA1) (Fig. 2c).
Confirmation of differentially expressed proteins
To validate our observation on the proteomics results,
western immunoblotting was exploited to evaluate the
expressions of Diablo, profilin 1, TPI1, NDUFAF1 and
PSMF1/PI31. These five proteins were targeted based on
their respective high-fold alterations except profilin 1
and potential relevance to cell proliferation and apop-
tosis. Consistent with the proteomics data, the results of
western immunoblotting demonstrated that Diablo,
profilin 1, TPI1, NDUFAF1 and PSMF1/PI31 were up-
regulated in PEE-treated T24 cells for 36 h (Fig. 3).
Previous findings demonstrated that profilin 1
over-expression increases phosphatase and tensin
homolog (PTEN) protein synthesis while PTEN gene
up-regulation inhibits Akt activity [15, 16]. In ac-
cordance with previous findings our study showed
that the exposure of T24 cell to 50 μg/mL PEE
could raise PTEN gene expression probably due to
Fig. 2 Lavapruple stained 2-DE polyacrylamide gel maps of untreated and PEE-treated T24 cells. The gel pair shown was the representative of 9
pairs of (a) 0.5 % (v/v) DMSO-incubated T24 cells and (b) PEE-incubated T24 cells. Protein lysates were prepared from 50 μg/mL PEE-treated
human T24 cells for 36 h as mentioned in the supplementary data. 100 μg proteins were loaded on linear pH 4–7 gradient strip followed by
vertical separation on 12.5 % (w/v) SDS polyacrylamide gels as described in section 2. The numbers indicated on the top of the gel indicated the
pH range and those on the left shown the approximate molecular mass (kDa) determined by Bio-Rad protein markers. The differentially expressed
spots were demonstrated by arrows. 19 spots were found to be up-regulated (spots 1–19) in PEE-affected cell and 1 spot was under-expressed
(spot A). c IPA Results
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profilin 1 over-expression and in turn dwindled
phospho-Akt expression, which barely influenced Akt
protein expression (Fig. 4). Furthermore, PEE treatment
could inhibit the expression of mTOR phosphorylated at
S2448, which is the catalytic subunit of mTORC1 complex
[17] (Fig. 4) and thus might interfere with the nutrient
metabolism or energy production in cancer cell. It has
been suggested that mTORC1 contains mTOR phosphor-
ylated predominantly on S2448 and inhibition of mTOR
S2448 phosphorylation correlates with the decreased
mTORC1 activity [17]. Reduced expression levels of p-Akt
and downstream phosphorylated mTOR (S2448) were
also observed in PEE-treated TSGH8301 cell (Fig. 5).
The above results suggested that through the up-regu-
lation of profilin 1 expression PEE exposure could inhibit
Akt/mTOR pathway which plays a significant role in
carcinogenesis.
Our results showed that PEE treatment cause increased
PI31 gene expression, suggesting that proteasome activity
might be inhibited in PEE-treated UBUC cell. Suppression
of proteasome activity may prevent activation/transloca-
tion of NFκB to the nucleus to activate downstream path-
ways [18]. Results of western immunoblotting against
RelA/p65 component of NF-κB demonstrated that PEE
treatment for 48 h decreased the amount of RelA/p65
both in the cytoplasm and nucleus of T24 cell (Fig. 4).
RelA/p65 along with p50 subunit moves to nucleus to ac-
tivate the target genes when NF-κB is activated.
In the apoptotic pathway induced by damaged mito-
chondria, mitochondria release multiple pro-apoptotic
proteins, such as Smac/Diablo, AIF, HtrA2 and EndoG
along with cytochrome C. Smac/Diablo can bind to X-
linked inhibitor of apoptosis protein (XIAP) and thus
prevent XIAP to inhibit apoptosis [19]. Our results dem-
onstrated that PEE incubation up-regulated Smac/Diablo
expression (Fig. 3) while reduced XIAP expression
(Fig. 4) in T24 cell and Diablo amount was also in-
creased in PEE-treated TSGH8301 cell (Fig. 5), implicat-
ing that PEE treatment could induce apoptosis through
damaged mitochondria.
Table 1 Differentially expressed proteins identified by tandem mass spectrometrya









1 ubiquilin 1 (UBQLN1) 5/9 4.8/56.2 5.2/62.5 10 10.34 119583063 +2.73
2 DNA polymerase ε subunit 3 (POLE3) 5/9 4.7/20.2 4.68/16.86 6 32.65 119607787 +7.58
3 eukaryotic translation initiation
factor 5A (eIF5A)
6/9 5/19.6 5.07/16.83 4 36.36 119610625 +1.78
4 tumor protein D54 (TPD52L2) 6/9 4.9/29.9 5.26/22.24 8 44.66 11125673 +12.84
5 phosphohistidine phosphatase 1 (PHPT1) 6/9 5.3/17.6 5.65/13.83 2 22.4 11191302 +5.12
6 proteasome inhibitor subunit 1
(PSMF1/PI31)
5/9 5.1/32.3 5.42/29.82 6 25.83 10432572 +3.97
7 B-cell lymphoma/leukemia 10 (BCL 10) 5/9 5.3/31.8 5.57/26.25 3 12.02 119593614 +2.9
8 dUTP pyrophosphatase (DUT) 5/9 5.5/21.2 6.15/17.75 5 42.07 10257385 +6.81
9 prefoldin subunit 5 (PFDN5) 5/9 5.8/19 5.94/17.33 9 57.79 119617089 +2.51
10 peflin (PEF1) 7/9 5.8/30.8 4.84/28.22 7 23.6 119628003 +6.31
11 triosephosphate isomerase 1 (TPI1) 5/9 6.2/28 5.65/30.79 8 39.86 119609128 +6.27
12 26S proteasome non-ATPase regulatory
subunit 9 (PSMD9)
5/9 6.3/30.5 6.46/24.68 2 9.42 119618700 +7.17
13 NADH dehydrogenase (ubiquinone) 1 α
subcomplex assembly factor 1 (NDUFAF1)
5/9 6.3/34.9 7.11/37.76 4 17.43 119612893 +5.2
14 transgelin 2 (TAGLN2) 5/9 6.9/22.6 8.41/22.39 10 53.27 119573145 +3.2
15 Diablo (DIABLO) 5/9 4.8/21.5 5.67/27.16 10 43.51 10437144 +3.94
16 BCL2-associated athanogene 2 (BAG2) 5/9 5.9/26.3 6.25/23.77 9 43.60 115528700 +4.71
17 translin-associated factor X (TSNAX) 5/9 6.2/33.3 6.10/33.11 8 42.41 119590369 +6.54
18 profilin 1 (PFN1) 5/9 6.8/17.9 8.44/15.05 7 65.00 119610787 +1.57
19 cofilin (CFL1) 5/9 7.0/19.0 8.22/18.50 10 56.02 116848 +2.86
A F-actin-capping protein subunit alpha-1
(CAPZA1)
5/9 5.2/36.8 5.45/32.92 10 41.26 119576929 −1.93
aMatched peptide number: Number of peptides matched with protein in MS/MS query. Coverage: Total percentage of amino acid sequence covered by peptides
identified by MS/MS analyses
bThe detail data of MS/MS identification for each peptide was provided in Additional file 2: Table S2, supporting information
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Discussion
Our previous studies have shown that PEE treatment
could inhibit UBUC via evoking cell apoptosis [12]. In
this study, we further found that PEE treatment could
restrict UBUC cell proliferation and migration. To inves-
tigate the specific proteins affected by PEE incubation in
UBUC cells, gel-based proteomics was carried out to
shed light on the molecular mechanism underlying can-
cer intervention by PEE exposure through provoking cell
apoptosis and inhibiting cell proliferation/migration. In
this research, 20 differentially expressed proteins were
found upon treatment of PEE to T24 cells with 19 up-
regulated and 1 down-regulated proteins respectively.
Among de-regulated proteins, PHPT1 protein plays a
role in lung cancer cell migration/invasion and is re-
vealed to be associated with cytoskeleton reorganization
[20]. Profilin 1 and Cofilin are the members of a family
of actin-binding proteins, which participate in dynamic
turnover and restructuring of actin cytoskeleton [15, 21].
Transgelin-2 is a cytoskeletal protein with actin-binding
activity shown to be a tumor suppressor in colorectal
carcinoma [22]. It has been postulated that cytoskeleton
remodeling plays a pivotal role in cancer cell migration
and also in regulating the morphologic and phenotypic
events of a malignant cell. Besides, apoptosis is generally
preceded by the pronounced changes of actin cytoskel-
eton [23]. Consistent with the above observations, re-
sults of this examination suggested that PEE treatment
might provoke the rearrangement of cytoskeleton struc-
ture of UBUC cells through disturbing the expressions
of cytoskeletal components and thus retard UBUC cell
proliferation/migration. This study provided a clue for
more investigation of the impacts of PEE on cytoskel-
eton structure in UBUC cell.
Previous documented findings demonstrated that aug-
mented profilin 1 synthesis can increase PTEN gene ex-
pression in breast cancer cell [15]. PTEN protein serves
as a phosphatase to dephosphorylate PIP3 to become
PIP2. This dephosphorylation results in inhibition of Akt
protein activity and thus Akt signaling pathway which
Fig. 3 Confirmation of the impacts of PEE on the expression levels of diablo, profilin 1, TPI1, NADUFAF1, PI31 in T24 cell by western
immunoblotting. a Diablo. b Profilin 1. c TPI1. d NADUFAF1. e PI31. Human T24 cells were incubated with 50 μg/mL PEE for various durations
(hours). Western immunoblotting was carried out as described in section 2. The blot was the typical data of three independent studies. The
protein expression fold (mean ± S.D.) was expressed as the ratio of normalized intensity (observed protein/actin or GAPDH) at each time point
divided by that at the beginning of treatment (0 h). * and ** represented P < 0.05 and P < 0.001 respectively as compared to untreated cell using
Student’s t-test
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plays a central role in protein synthesis, metabolism and
cell proliferation [16]. Akt can phosphorylate tuberin/
TSC2 to prevent the inhibition of mTORC1 complex
(mTOR-raptor complex). mTORC1 integrates multiple
signals to promote either cellular growth in favorable
conditions or catabolic processes in unfavorable con-
ditions while mTORC2 (mTOR-rictor complex) is
related to actin organization. Many documented evi-
dences indicated that impaired PTEN/Akt/mTOR sig-
naling pathway plays a key role in tumorigenesis in
many tumors [24]. In accordance with the aforemen-
tioned findings, our present data suggested that PEE
treatment increased profilin 1 expression to up-regulate
PTEN gene expression, which might in turn inhibited
Akt/mTORC1 signaling pathway to prevent UBUC cell
proliferation/migration.
The abnormal proteasomal activity contributes to
tumorigenesis by offering cancer cell with anti-apoptotic
protection and a survival advantage [25]. Our findings
implicated that PEE treatment could alter the expres-
sions of several genes associated with 26S proteasome
activity (PSMD9, UBQLN1, PSMF1) in UBUC cells to
disturb cell proliferation. PSMF1/PI31 can bind to 20S
catalytic particle of 26S proteasome to hinder substrate
access to the enzymatic core and thus results in the in-
hibition of proteasomal activity [26]. PSMD9 is a protea-
somal assembly chaperone [27]. Ubiquilin-1 is thought
to functionally link the ubiquitination machinery to the
proteasome to effect in vivo protein degradation [28].
Suppression of proteasomal activity may prevent degrad-
ation of IκB (endogenous inhibitor of NF-κB) and subse-
quent activation/translocation of NFκB to the nucleus to
Fig. 4 Effects of PEE on the expression levels of PTEN/Akt/mTOR pathway, NFκB and XIAP in T24 cell. a PTEN. b Akt. c p-Akt. d mTOR. e Rel A in
cytosol. f Rel A in nucleus. g XIAP. An additional file [Additional file 1] showed the preparation of nuclear and cytoplasmic extracts. Legends were
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Fig. 5 Impacts of PEE on the expression levels of Diablo, p-Akt and mTOR in TSGH8301 cell. a p-Akt. b mTOR. c Diablo
Wu et al. BMC Complementary and Alternative Medicine  (2016) 16:96 Page 8 of 10
activate downstream pathways [29]. NFκB plays an im-
portant role in tumorigenesis of many tumors by pro-
moting cell proliferation, migration and suppression of
apoptosis [18]. Our study indicated that PEE treatment
could inhibit NFκB activation possibly through evoking
PSMF1/PI31 over-expression to prevent the proteasomal
degradation of IκB.
Among PEE-induced de-regulated proteins, BCL10,
diablo, peflin, TPD52L2, eIF5A and BAG2 are shown to
be involved in regulating cell apoptosis. Several findings
suggested that BCL10 is an apoptotic regulatory protein
and participates in Apaf1/caspase 9-mediated cell death
pathway [30]. eIF5A is the only known protein to be reg-
ulated by the post-translational formation of a hypusine
residue. Recent studies have indicated that unhypusi-
nated eIF5A is pro-apoptotic and only observed during
apoptosis [31]. Our proteomics data showed that PEE in-
cubation could increase eIF5A gene expression but fur-
ther investigation was required to determine whether
unhypusinated eIF5A level was increased in PEE-treated
T24 cell. TPD52L2 can interact with TPD52L1 protein
which positively regulates apoptosis signal-regulating
kinase 1 (ASK1)-induced apoptosis [32]. Peflin can regu-
late the activity of apoptosis-linked gene 2 (ALG-2)
which associates with Fas-executed apoptosis [33]. In
the apoptotic pathway, the caspapse activities can be
inhibited directly by inhibitor of apoptosis (IAP) protein
[19]. During the mitochondrial apoptotic process, the in-
hibitory function of XIAP, a ubiquitous member of IAP
family, can be antagonized by Smac/Diablo and Omi/
HtrA2 which are also released from mitochondria along
with cytochrome c. BAG2 exhibits pro-apoptotic proper-
ties and is demonstrated to be up-regulated in prote-
asome inhibitor-induced apoptosis in thyroid carcinoma
cell [34]. Our present results demonstrated that PEE ex-
posure could increase the aforementioned apoptotic pro-
teins to provoke UBUC cell apoptosis.
Some of dys-regulated proteins evoked by PEE
treatment might attribute to the mitochondrial dam-
age and nuclear change (nuclear fragmentation, chro-
matin condensation and DNA fragmentation) which
are the characteristics of cell apoptosis. Translin/
TRAX protein complex (C3PO) plays roles in very
important key cellular processes such as cell growth
regulation, genome stability regulation and carcinogenesis
[35]. NAUFAF1 is a chaperone protein involved in the as-
sembly of the mitochondrial NADH:ubiquinone oxidore-
ductase complex (complex I) which transfers the electron
from NADH to ubiquinone (coenzyme Q) in the first step
of the mitochondrial respiratory chain [36]. Cancer cells
proliferate very rapidly and rely on high metabolic activ-
ities. To meet high energy demand, tumor cells exploit
aerobic glycolysis to acquire the energy from glucose
(Warburg effect). During glycolysis only one of two
triosephosphates formed by aldolase-glyceraldehyde-3-
phosphate-is degraded in the subsequent steps. The other
product, dihydroxyacetone phosphate, is rapidly and re-
versibly converted to glyceraldehyde-3-phosphate by TPI1
protein [37].
Conclusion
In conclusion, this study showed that exposure of
UBUC cell to PEE might result in (1) apoptosis; (2)
proteasome structure/activity alteration; (3) cytoskel-
eton rearrangement; (4) AKT/mTOR signaling path-
way inhibition and (5) impaired aerobic glycolysis.
Besides, IPA analyses showed that the de-regulated
proteins were involved in apoptosis, proliferation, gly-
colysis, DNA metabolism. The results of this study
provide a global picture to further investigate the an-
ticancer molecular mechanism of PEE.
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